XML 53 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity (Tables)
12 Months Ended
Jun. 30, 2021
Stockholders' Equity [Abstract]  
Schedule Of Option Activity

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Contractual
Term in Years

Outstanding at beginning of period

1,068 

$

89.05 

4.4

Granted

56 

210.18 

Exercised

(64)

62.05 

Forfeited

-

-

Outstanding at end of period

1,060 

$

97.01 

3.7

Options exercisable at end of period

804 

$

82.11 

3.2

Options vested and expected to vest at end of period

1,050 

$

96.37 

3.7

Schedule Of Activity Of Restricted Stock Units

Restricted
Stock
Units

Weighted
Average
Grant-Date
Fair Value

Weighted
Average
Remaining
Contractual
Term in Years

Outstanding at beginning of period

1,132 

$

103.77 

1.6

Granted

277 

209.02 

Vested*

(704)

84.87 

Performance factor adjustment

209 

-

Expired / cancelled

(34)

119.64 

Forfeited

(5)

119.64 

Outstanding at end of period

875 

$

145.19 

1.5

* Includes 235 thousand shares netted for tax.

Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted

2021

2020

2019

Stock options:

Weighted average grant date fair value

$

53.67

$

32.14

$

21.92

Weighted average risk-free interest rate

0.37%

1.58%

2.96%

Expected life in years

4.9

4.9

4.9

Dividend yield

0.75%

1.07%

1.34% - 1.46%

Expected volatility

31%

25%

23%

ESPP purchase rights:

Weighted average grant date fair value

$

48.18

$

31.82

$

22.12

Weighted average risk-free interest rate

0.1%

1.6%

2.4%

Expected life in years

6 months

6 months

6 months

Dividend yield

0.79% - 0.98%

0.98% - 1.42%

1.40% - 1.47%

Expected volatility

30% - 60%

23% - 60%

23%

Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized

2021

2020

2019

Cost of sales

$

4,153 

$

3,703 

$

3,043 

Selling, general and administrative expenses

51,727 

47,265 

42,700 

Research and development expenses

8,047 

6,591 

6,330 

Stock-based compensation costs

63,927 

57,559 

52,073 

Tax benefit

(23,346)

(39,534)

(26,658)

Stock-based compensation costs, net of tax benefit

$

40,581 

$

18,025 

$

25,415